Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun:178:104791.
doi: 10.1016/j.antiviral.2020.104791. Epub 2020 Apr 7.

Type 1 interferons as a potential treatment against COVID-19

Erwan Sallard  1 , François-Xavier Lescure  2 , Yazdan Yazdanpanah  2 , France Mentre  3 , Nathan Peiffer-Smadja  4
Affiliations

Type 1 interferons as a potential treatment against COVID-19

Erwan Sallard et al. Antiviral Res. 2020 Jun.

Abstract

Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.

Keywords: COVID-19; Interferon; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest None.

References

    1. Al-Tawfiq J.A., Momattin H., Dib J., Memish Z.A. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 2014;20:42–46. doi: 10.1016/j.ijid.2013.12.003. - DOI - PMC - PubMed
    1. Arabi Y.M., Shalhoub S., Al-Omari A., Mandourah Y., Al-Hameed F., Sindi A., Alraddadi B., Al-Motairi A., Al-Khatib K., Abdul-Mommin A., Qushmaq I.A., Mady A., Solaiman O., Al-Aithan A., Balkhy H.H., Al-Raddadi R., Rajab A., Al-Mekhlafi G.A., Al-Harthy A., Kharaba A., Al-Jabbary A., Pinto R., Sadat M., Al-Mutairi H., Al-Qasim E., Jose J., Deeb A.M., Merson L., Hayden F.G., Fowler R., Aldawood A.S. Effect of ribavirin and interferon on the outcome of critically ill patients with MERS. Am. J. Respir. Crit. Care Med. 2017;195:A6067.
    1. Arabi Y.M., Alothman A., Balkhy H.H., Al-Dawood A., AlJohani S., Al Harbi S., Kojan S., Al Jeraisy M., Deeb A.M., Assiri A.M., Al-Hameed F., AlSaedi A., Mandourah Y., Almekhlafi G.A., Sherbeeni N.M., Elzein F.E., Memon J., Taha Y., Almotairi A., Maghrabi K.A., Qushmaq I., Al Bshabshe A., Kharaba A., Shalhoub S., Jose J., Fowler R.A., Hayden F.G., Hussein M.A., Martin G.S., Schoenfeld D.A., Walmsley S.L., Carson S., Harbi S. Al, Jeraisy M. Al, Muhaidib M. Al, Musharaf S., Anizi H. Al, Dael R., AlMazroa M., Asiri A., Memish Z.A., Ghazal S.S., Alfaraj S.H., Harthy A. Al, Sulaiman M. Al, Mady A., Ahmad A., Almekhlafi Ghaleb A., Muhammed R., Samirrai S. Al, Awad S., Cabal R.C., Onazi B. Al, Aljuhani M., Vince M., Enani M. Al, Alqurashi A., Alenezi F., Alkhani N., Thaqafi A., Oraabi O. Al, Rifai J., Elsamadisi P., Medhat S.H., Basher S.A.B., Abduldhaher M., Bajhamoum W., Alahsa S.S., Bashir S., Al-Dossary I., Al-Muhainy Dammam B., Khobar S.S. Al, Alshahrani M.S., Al Jabri A., Farid M., Alaidarous A., Alseraihi W., Shahada H., Taif J.S. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19:1–13. doi: 10.1186/s13063-017-2427-0. - DOI - PMC - PubMed
    1. Bellingan G., Maksimow M., Howell D.C., Stotz M., Beale R., Beatty M., Walsh T., Binning A., Davidson A., Kuper M., Shah S., Cooper J., Waris M., Yegutkin G.G., Jalkanen J., Salmi M., Piippo I., Jalkanen M., Montgomery H., Jalkanen S. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir. Med. 2014;2:98–107. doi: 10.1016/S2213-2600(13)70259-5. - DOI - PubMed
    1. Belhadi D., Peiffer-Smadja N., Yazdanpanah Y., Mentré F., Laouénan C. A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. medRxiv. January. 2020 doi: 10.1101/2020.03.18.20038190. 2020.03.18.20038190. - DOI